RATIONALE: IVIG (Intravenous Immunoglobulin) and SCIG (Subcutaneous Immunoglobulin) have been regarded as therapeutically equivalent treatments for primary immunodeficiency diseases (PIDDs). IgG trough level is used as a monitoring measure for infection prevention. A systematic review and meta-analysis was performed in patients with PIDD and relationship between IgG dosing, trough IgG levels with overall infection incidence were evaluated. METHODS: Medline, EMBASE, Cochrane, Central and Scopus were searched for studies published from Jan 2000-June 2018, fulfilling the inclusion criteria. DerSimonian and Laird random-effect method was used to pool difference of IgG trough levels. Random-effect meta-regression was used to evaluate infection incidence per 100 mg/dl IgG trough increase through IVIG and SCIG. Department of Pediatrics, Division of Allergy, Immunology, and Rheumatology; University of North Carolina, Chapel Hill, NC. RATIONALE: Epigenetic alterations partly mediated by histone H3 lysine 27 (H3K27) demethylase UTX are critical for humoral and cellular immunity against chronic viral infections. Whether UTX-modulated epigenetic changes impact type 2 immunity in allergic sensitization and type 2/regulatory immunity associated with chronic helminth infection is unclear. METHODS: We used mice with UTX-deficient T cells (UTX-TCD) to assess whether T cell-specific UTX expression affects 1) IgE production following subcutaneous sensitization to galactose-alpha-1,3-galactose (alpha-gal) and 2) the immunosuppressive effects of preexisting intestinal helminth infection on antibody responses to intramuscular vaccination. We sensitized wildtype (WT) C57Bl/6J or UTX-TCD mice 3 times at 1 to 2-week intervals with 50 micrograms of lone star tick (Amblyomma americanum)-derived salivary gland extract (TSGE). We examined polyclonal and antigen-specific IgE and CD4 + T cell responses 2 weeks after the last subcutaneous injection. In separate experiments, WT and UTX-TCD mice were infected or not with the mouse intestinal parasitic nematode Heligmosomoides polygyrus bakeri and vaccinated intramuscularly twice at 1-week intervals with chicken-egg ovalbumin adsorbed to alum (OVA-alum University of South Florida and Johns Hopkins All Children's Hospital, St Petersburg, FL. RATIONALE: Rituximab is an anti-CD20 monoclonal antibody used in both pediatric and adult patients. Despite its widespread use, immunologic monitoring has not been consistent among subspecialties. METHODS: We performed a retrospective review of pediatric patients receiving rituximab in the Partners Healthcare system between 1997-2017. We evaluated baseline demographics, indication for rituximab, immunologic evaluation pre-and post-rituximab, IVIG use, and infectious outcomes. RESULTS: We identified 48 pediatric patients who had received rituximab. There were 27 (56%) female patients. The average age at the time of rituximab administration was 9 years old (range 1-14). Indications for rituximab included primary diagnoses in hematology (n515), neurology (n510), renal (n59), oncology (n55), rheumatology (n53), dermatology (n51), ophthalmology (n51) and gastroenterology (n51). In this cohort, 14/48 (29%) had peripheral flow cytometry sent prior to initiation of rituximab and 32/48 patients (66%) had post-rituximab flow cytometry sent. Pre-rituximab immunoglobulins were evaluated in 26/48 (54%) patients, while 36/48 (75%) had at least one post-rituximab immunoglobulin level sent. 33/48 (69%) patients had infectious complications following rituximab. While a higher percentage of patients with hypogammaglobulinemia post-rituximab had infections compared to those without hypogammaglobulinemia (86% vs 53%), this did not reach statistical significance (p50.059). 26 patients (54%) received IVIG following rituximab. CONCLUSIONS: Immunological monitoring of pediatric patients is not consistent across specialties. Particularly in pediatrics, where immune dysregulation may present in other specialties prior to immunology, it may be helpful to evaluate baseline immunoglobulins and flow cytometry prior to rituximab to evaluate for pre-existing immune deficiency or dysregulation that warrants increased monitoring. J ALLERGY CLIN IMMUNOL VOLUME 143, NUMBER 2 Abstracts AB205 SUNDAY
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